| scholarly article | Q13442814 |
| P50 | author | Stefan Lohmander | Q39752104 |
| P2093 | author name string | D Heinegård | |
| J Hardin | |||
| Y Henrotin | |||
| V B Kraus | |||
| A R Poole | |||
| S Cottrell | |||
| S Persiani | |||
| J Gardiner | |||
| G Matthews | |||
| P Garnero | |||
| A Ko | |||
| R Moskowitz | |||
| B Burnett | |||
| D Eyre | |||
| J Coindreau | |||
| M Todman | |||
| M Gendreau | |||
| J-C Rousseau | |||
| J Menetski | |||
| OARSI FDA Osteoarthritis Biomarkers Working Group | |||
| P2860 | cites work | Optimization of the fixed-flexion knee radiograph | Q81541543 |
| Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study | Q82771429 | ||
| Assessment of the utility of biomarkers of osteoarthritis in the guinea pig | Q83296983 | ||
| Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis | Q83925263 | ||
| A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis | Q78312280 | ||
| Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis | Q78387194 | ||
| Kellgren & Lawrence grade 1 osteophytes in the knee--doubtful or definite? | Q78849987 | ||
| Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis | Q79158458 | ||
| Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs | Q79448428 | ||
| Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation | Q80001948 | ||
| Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years | Q80502383 | ||
| COMP acts as a catalyst in collagen fibrillogenesis | Q80837951 | ||
| Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study | Q80845216 | ||
| Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints | Q81248117 | ||
| Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis | Q81300587 | ||
| Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing | Q81517363 | ||
| Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] | Q24816771 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis | Q28748487 | ||
| Radiological assessment of osteo-arthrosis | Q29614927 | ||
| One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status | Q31157327 | ||
| A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients | Q33249982 | ||
| Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis | Q33265934 | ||
| The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. | Q33542090 | ||
| Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study | Q34001775 | ||
| Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay | Q34140878 | ||
| Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies | Q34192717 | ||
| The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand | Q34196891 | ||
| Strategic paths for biomarker qualification | Q34750888 | ||
| Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis | Q35547384 | ||
| Markers of joint destruction: principles, problems, and potential | Q35550491 | ||
| Content and sulfation pattern of keratan sulfate in hip osteoarthritis using high performance liquid chromatography | Q74067855 | ||
| Collagen type II C-telopeptide fragments as an index of cartilage degradation | Q74514253 | ||
| Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis | Q35554303 | ||
| Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease | Q35613010 | ||
| Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study | Q35636890 | ||
| Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis | Q35637511 | ||
| Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. | Q35692131 | ||
| Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay | Q35706718 | ||
| The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis | Q36274389 | ||
| Classification of osteoarthritis biomarkers: a proposed approach. | Q36491949 | ||
| Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study | Q36493865 | ||
| Process map proposal for the validation of genomic biomarkers | Q36555934 | ||
| Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. | Q36753651 | ||
| Biomarker qualification pilot process at the US Food and Drug Administration | Q36780044 | ||
| Monitoring cartilage turnover | Q36793231 | ||
| Biological markers in osteoarthritis | Q36835538 | ||
| PIIANP and HELIXII diurnal variation | Q36884634 | ||
| Banking of biological fluids for studies of disease-associated protein biomarkers | Q36919974 | ||
| Type II collagen markers in osteoarthritis: what do they indicate? | Q36925336 | ||
| Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation | Q36954971 | ||
| Variation in osteoarthritis biomarkers from activity not food consumption | Q36980483 | ||
| Trabecular morphometry by fractal signature analysis is a novel marker of osteoarthritis progression | Q37011921 | ||
| Effect of an exercise and dietary intervention on serum biomarkers in overweight and obese adults with osteoarthritis of the knee | Q37029663 | ||
| Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis | Q37086756 | ||
| Serum protein signatures detect early radiographic osteoarthritis | Q37154116 | ||
| The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence | Q37175461 | ||
| The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? | Q37203491 | ||
| Collagen biomarkers for arthritis applications. | Q37277952 | ||
| Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers | Q37350908 | ||
| Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage | Q37365557 | ||
| Whither osteoarthritis biomarkers? | Q37378390 | ||
| Evidence for altered synthesis of type II collagen in patients with osteoarthritis | Q37388249 | ||
| Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development | Q37462448 | ||
| Molecular markers of processes in cartilage in joint disease. | Q37632518 | ||
| Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria | Q37696611 | ||
| Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri | Q39344079 | ||
| Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers | Q39367510 | ||
| Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association | Q39513001 | ||
| Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis | Q40303620 | ||
| The Food and Drug Administration's Osteoporosis Guidance Document: past, present, and future | Q40579997 | ||
| Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. | Q40900007 | ||
| Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube | Q41996281 | ||
| Novel synovial fluid recovery method allows for quantification of a marker of arthritis in mice | Q42060547 | ||
| Quantification of keratan sulfate in blood as a marker of cartilage catabolism | Q42203470 | ||
| Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. | Q42654166 | ||
| Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis | Q42909168 | ||
| Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation | Q43564129 | ||
| Urea as a passive transport marker for arthritis biomarker studies | Q43882922 | ||
| N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial | Q43904300 | ||
| Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography | Q44311441 | ||
| Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis | Q44670859 | ||
| Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. | Q44789264 | ||
| The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases | Q45215215 | ||
| Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA. | Q45928292 | ||
| Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease | Q46243933 | ||
| Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. | Q46357032 | ||
| Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities | Q46541397 | ||
| A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees | Q46548448 | ||
| The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation | Q46651873 | ||
| Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration | Q46664332 | ||
| Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial | Q46907359 | ||
| Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis | Q46939435 | ||
| Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. | Q46939851 | ||
| Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. | Q48592216 | ||
| Modulation of collagen fibrillogenesis by dentinal proteoglycans. | Q50769440 | ||
| Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. | Q51557915 | ||
| Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. | Q51566399 | ||
| Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. | Q52947167 | ||
| OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. | Q53290466 | ||
| Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. | Q53581205 | ||
| Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. | Q53624861 | ||
| Blood-based biomarkers for detecting mild osteoarthritis in the human knee. | Q54645757 | ||
| Change in joint space width: Hyaline articular cartilage loss or alteration in meniscus? | Q57244844 | ||
| Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: The Johnston county osteoarthritis project | Q57721652 | ||
| Soy protein may alleviate osteoarthritis symptoms | Q57880747 | ||
| Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy | Q59042643 | ||
| Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease | Q67273045 | ||
| Early Rheumatoid-Like Lesions in Rabbits Injected with Foreign Serum: Relationship to Localization of Immune Complexes in the Lining Tissues of Joints and Cellular Content of Synovial Fluid | Q67318046 | ||
| Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury | Q67531153 | ||
| Quantitation of chondroitin 4-sulfate and chondroitin 6-sulfate in pathologic joint fluid | Q67588581 | ||
| Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor | Q73064708 | ||
| P433 | issue | 5 | |
| P921 | main subject | biomarker | Q864574 |
| osteoarthritis | Q62736 | ||
| P304 | page(s) | 515-542 | |
| P577 | publication date | 2011-03-23 | |
| P1433 | published in | Osteoarthritis and Cartilage | Q7107605 |
| P1476 | title | Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis | |
| P478 | volume | 19 |
| Q36241253 | A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis |
| Q51296495 | A dissimilarity-based multiple classifier system for trabecular bone texture in detection and prediction of progression of knee osteoarthritis. |
| Q91286801 | A pilot study of peripheral blood DNA methylation models as predictors of knee osteoarthritis radiographic progression: data from the Osteoarthritis Initiative (OAI) |
| Q37221990 | Acute Molecular Changes in Synovial Fluid Following Human Knee Injury: Association With Early Clinical Outcomes |
| Q35907720 | Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. |
| Q34122276 | Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis |
| Q30561348 | Analysis of mass spectrometry data from the secretome of an explant model of articular cartilage exposed to pro-inflammatory and anti-inflammatory stimuli using machine learning. |
| Q39100190 | Analysis of the trajectory of osteoarthritis development in a mouse model by serial near-infrared fluorescence imaging of matrix metalloproteinase activities |
| Q26998936 | Animal Models of Osteoarthritis: Comparisons and Key Considerations |
| Q38074887 | Animal models of osteoarthritis: challenges of model selection and analysis |
| Q28072990 | Animal models of osteoarthritis: classification, update, and measurement of outcomes |
| Q35634979 | Applications of proteomics to osteoarthritis, a musculoskeletal disease characterized by aging |
| Q64913227 | Assessment of early tibiofemoral joint space width changes after anterior cruciate ligament injury and reconstruction: a matched case-control study. |
| Q64068639 | Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study |
| Q47121927 | Association between ultrasound-detected synovitis and knee pain: a population-based case-control study with both cross-sectional and follow-up data |
| Q64966958 | Biomarkers as drug development tools: discovery, validation, qualification and use. |
| Q27002552 | Biomarkers for osteoarthritis: current position and steps towards further validation |
| Q35146138 | Biomarkers of incident radiographic knee osteoarthritis: do they vary by chronic knee symptoms? |
| Q34232764 | Blood cells transcriptomics as source of potential biomarkers of articular health improvement: effects of oral intake of a rooster combs extract rich in hyaluronic acid |
| Q58570637 | Bulgarian rheumatology: science and practice in a cost-constrained environment |
| Q28081433 | Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use |
| Q35197151 | Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis |
| Q47375322 | Cartilage oligomeric protein, matrix metalloproteinase-3, and Coll2-1 as serum biomarkers in knee osteoarthritis: a cross-sectional study. |
| Q34614103 | Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). |
| Q36111296 | Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis |
| Q34078519 | Cyclic phosphatidic acid relieves osteoarthritis symptoms |
| Q34554878 | Daily oral consumption of hydrolyzed type 1 collagen is chondroprotective and anti-inflammatory in murine posttraumatic osteoarthritis. |
| Q33655900 | Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial |
| Q42099673 | Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited |
| Q33669014 | Discovery of circulating proteins associated to knee radiographic osteoarthritis |
| Q57141249 | EUROVISCO Guidelines for the Design and Conduct of Clinical Trials Assessing the Disease-Modifying Effect of Knee Viscosupplementation |
| Q37658228 | Effect of age-related cartilage turnover on serum C-telopeptide of collagen type II and osteocalcin levels in growing rabbits with and without surgically induced osteoarthritis |
| Q36255352 | Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA |
| Q36156938 | Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients |
| Q50459670 | Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial. |
| Q37562358 | Enhanced expression of the central survival of motor neuron (SMN) protein during the pathogenesis of osteoarthritis |
| Q38848622 | Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH/OARSI OA Biomarkers Consortium |
| Q49804388 | Fib3-3 as a Biomarker for Osteoarthritis in a Rat Model with Metabolic Dysregulation. |
| Q50584701 | Fractalkine (CX3CL1): a biomarker reflecting symptomatic severity in patients with knee osteoarthritis. |
| Q58801272 | GPR120 is an important inflammatory regulator in the development of osteoarthritis |
| Q55411352 | Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo. |
| Q36949072 | How to define responders in osteoarthritis |
| Q58628948 | Identification and validation of early biomarkers of osteoarthritis in companion animals: Are we ready for the challenge? |
| Q37170273 | Immediate Administration of Intraarticular Triamcinolone Acetonide After Joint Injury Modulates Molecular Outcomes Associated With Early Synovitis |
| Q37582530 | Impact of physical activity and mechanical loading on biomarkers typically used in osteoarthritis assessment: current concepts and knowledge gaps |
| Q38062383 | Impact of treatments for osteoporosis on cartilage biomarkers in humans. |
| Q41555039 | In vivo efficacy of fresh versus frozen osteochondral allografts in the goat at 6 months is associated with PRG4 secretion |
| Q41829080 | In vivo optical imaging of early osteoarthritis using an antibody specific to damaged arthritic cartilage |
| Q33755536 | Indian hedgehog in synovial fluid is a novel marker for early cartilage lesions in human knee joint |
| Q26862126 | Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis |
| Q87511725 | Intra-articular zoledronic acid in a rat osteoarthritis model: significant reduced synovitis may indicate chondroprotective effect |
| Q36332977 | Investigation of random walks knee cartilage segmentation model using inter-observer reproducibility: Data from the osteoarthritis initiative |
| Q90128829 | LncRNA DNM3OS promotes proliferation and inhibits apoptosis through modulating IGF1 expression by sponging MiR-126 in CHON-001 cells |
| Q36422029 | Magnetic Capture of a Molecular Biomarker from Synovial Fluid in a Rat Model of Knee Osteoarthritis |
| Q45807411 | Meta-analysis identifies loci affecting levels of the potential osteoarthritis biomarkers sCOMP and uCTX-II with genome wide significance |
| Q35222605 | Molecular changes in articular cartilage and subchondral bone in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis |
| Q36205166 | Nanomedicines for chronic non-infectious arthritis: the clinician's perspective |
| Q92594517 | New Drug Treatments for Osteoarthritis: What is on the Horizon? |
| Q54987147 | Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. |
| Q89870839 | Novel adipokine associated with OA: retinol binding protein 4 (RBP4) is produced by cartilage and is correlated with MMPs in osteoarthritis patients |
| Q33947178 | Novel cartilage oligomeric matrix protein (COMP) neoepitopes identified in synovial fluids from patients with joint diseases using affinity chromatography and mass spectrometry. |
| Q34475498 | OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. |
| Q26781301 | On the predictive utility of animal models of osteoarthritis |
| Q34728871 | Osteoarthritis year 2010 in review: biochemical markers |
| Q26771893 | Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria |
| Q38104445 | Pathogenesis of epiphyseal osteochondrosis |
| Q42094646 | Patient Evaluation and OA Study Design: OARSI/Biomarker Qualification |
| Q36800983 | Personalized medicine for osteoarthritis: where are we now? |
| Q37809746 | Pharmacologic therapy for osteoarthritis--the era of disease modification |
| Q47784319 | Physical activity levels and quality of life relate to collagen turnover and inflammation changes after running |
| Q47981125 | Possible Involvement of Serum and Synovial Fluid Resistin in Knee Osteoarthritis: Cartilage Damage, Clinical, and Radiological Links. |
| Q36403388 | Predicting Knee Osteoarthritis |
| Q93135737 | Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis |
| Q36050803 | Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium |
| Q47358933 | Predictive value of MRI features for development of radiographic osteoarthritis in a cohort of participants with pre-radiographic knee osteoarthritis-the CHECK study |
| Q27022211 | Prognostic biomarkers in osteoarthritis |
| Q92310100 | Recent advances in understanding the phenotypes of osteoarthritis |
| Q33733817 | Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized |
| Q52638394 | Relationship between markers of type II collagen metabolism and tibiofemoral joint space width changes after ACL injury and reconstruction. |
| Q33900824 | Relationship between synovial fluid ARGS-aggrecan fragments, cytokines, MMPs, and TIMPs following acute ACL injury: A cross-sectional study |
| Q38950280 | Relationship between synovial fluid biomarkers of articular cartilage metabolism and the patient's perspective of outcome depends on the severity of articular cartilage damage following ACL trauma |
| Q37602869 | Republished: Value of biomarkers in osteoarthritis: current status and perspectives |
| Q38723831 | Review of Soluble Biomarkers of Osteoarthritis: Lessons From Animal Models |
| Q64099427 | Revisiting predictive biomarkers of musculoskeletal injury in thoroughbred racehorses: longitudinal study in polish population |
| Q34379622 | Running a marathon induces changes in adipokine levels and in markers of cartilage degradation--novel role for resistin. |
| Q48745658 | Science in brief: Report on the Havemeyer Foundation workshop on equine musculoskeletal biomarkers--current knowledge and future needs. |
| Q47151673 | Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of normal joint cartilage pursuant to Article 13(5) of Regulation (EC) No 1924/2006 |
| Q42148121 | Sequential depletion of human serum for the search of osteoarthritis biomarkers |
| Q37710696 | Serum and synovial fluid lipidomic profiles predict obesity-associated osteoarthritis, synovitis, and wound repair. |
| Q38869739 | Societal and Economic Effect of Meniscus Scaffold Procedures for Irreparable Meniscus Injuries. |
| Q92059853 | Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update |
| Q28077398 | Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine |
| Q52639586 | Subchondral trabecular bone integrity changes following ACL injury and reconstruction: a cohort study with a nested, matched case-control analysis. |
| Q58734897 | Superoxide dismutase activity is significantly lower in end-stage osteoarthritic cartilage than non-osteoarthritic cartilage |
| Q52644417 | Synovial Fluid Eotaxin-1 Levels May Reflect Disease Progression in Primary Knee Osteoarthritis Among Elderly Han Chinese: A Cross-Sectional Study. |
| Q37612457 | TSG-6 activity as a novel biomarker of progression in knee osteoarthritis |
| Q26850147 | Targets, models and challenges in osteoarthritis research |
| Q39783224 | The Association Between Serum Biomarkers of Collagen Turnover and Subsequent Anterior Cruciate Ligament Rupture |
| Q42705148 | The Need for Predictive, Prognostic, Objective and Complementary Blood-Based Biomarkers in Osteoarthritis (OA). |
| Q27025115 | The evolving role of biomarkers for osteoarthritis |
| Q37213622 | The future of osteoarthritis therapeutics: targeted pharmacological therapy |
| Q39836529 | The potential biochemical markers of Kashin-Beck disease: a meta-analysis |
| Q92828667 | The role of intra-articular administration of Fetuin-A in post-traumatic knee osteoarthritis: an experimental study in a rat model |
| Q46644754 | Transcriptional profiling of articular cartilage in a porcine model of early post-traumatic osteoarthritis. |
| Q37267571 | Value of biomarkers in osteoarthritis: current status and perspectives. |
| Q34459809 | What is the utility of biomarkers for assessing the pathophysiology of hip osteoarthritis? A systematic review. |
| Q42269793 | rAAV-mediated overexpression of TGF-β stably restructures human osteoarthritic articular cartilage in situ |
Search more.